Search

 
 
 
Turning Point Prices IPO, Raising $166M to Test Cancer Drugs

TURNING POINT PRICES IPO, RAISING $166M TO TEST CANCER DRUGS

Turning Point Therapeutics raised more than $166 million in its IPO, pricing at the top of its range and putting nearly 2 million more...

Roche Lifts Full Year Outlook, Sees Higher Dividend Following ‘Strong' First Quarter Sales

ROCHE LIFTS FULL YEAR OUTLOOK, SEES HIGHER DIVIDEND FOLLOWING ‘STRONG' FIRST QUARTER SALES

Swiss drugmaker Roche said early Wednesday that it started the year with “strong” sales growth in the first quarter, driven by newly...

 
 
 
Afterwork: Roch Barbot Mixes It Up with GQ France

AFTERWORK: ROCH BARBOT MIXES IT UP WITH GQ FRANCE

Roch Barbot stirs up fashion envy as he tackles afterwork style for GQ France. The French model poses for the lens of photographer...

Angelina Jolie Implores World Leaders to Address ''Alarming'' Gender Inequalities in U.N. Speech

ANGELINA JOLIE IMPLORES WORLD LEADERS TO ADDRESS ''ALARMING'' GENDER INEQUALITIES IN U.N. SPEECH

Angelina Jolie is making a plea for action. On Friday, March 29, the humanitarian took to the stage at the United Nations in New York...

 
 
 
FDA approves Roche's Tecentriq for first-line, extensive-stage small-cell lung cancer

FDA APPROVES ROCHE'S TECENTRIQ FOR FIRST-LINE, EXTENSIVE-STAGE SMALL-CELL LUNG CANCER

The PD-L1 inhibitor is the first new drug for ES-SCLC in more than 20 years. Meanwhile, Merck is also running a Phase III study of...

Bio Roundup: Golumbeski's Legacy, CRISPR Moratorium, Rebate Week & More

BIO ROUNDUP: GOLUMBESKI'S LEGACY, CRISPR MORATORIUM, REBATE WEEK & MORE

While all eyes in the biopharmaceutical world are currently trained on Bristol-Myers Squibb's proposal to buy Celgene for $74 billion...

 
 
 
Roche's Tecentriq approved as first immunotherapy drug for breast cancer

ROCHE'S TECENTRIQ APPROVED AS FIRST IMMUNOTHERAPY DRUG FOR BREAST CANCER

The drug received accelerated approval for combination with Celgene's Abraxane based on Phase III data. According to a study, PD-L1-positive...

San Diego Life Sciences Roundup: ResMed, Alexandria GradLabs & More

SAN DIEGO LIFE SCIENCES ROUNDUP: RESMED, ALEXANDRIA GRADLABS & MORE

Spring has sprung, and it's shaping up to be another busy season for San Diego's life sciences community. As we head into the weekend,...

 
 
 
“Form-Generating is Similar to Music - You Try to Compose Music and Suddenly the Melody Comes”: In Conversation with Kevin Roche

“FORM-GENERATING IS SIMILAR TO MUSIC - YOU TRY TO COMPOSE MUSIC AND SUDDENLY THE MELODY COMES”: IN CONVERSATION WITH KEVIN ROCHE

National Conference Center, Dublin, Ireland, 2010 © Kevin Roche John Dinkeloo and Associates American architect Kevin Roche passed...

Kevin Roche, Celebrated Designer of Post-War America, Passes away at 96

KEVIN ROCHE, CELEBRATED DESIGNER OF POST-WAR AMERICA, PASSES AWAY AT 96

Kevin Roche with Scale Model © KRJDA Kevin Roche, the Irish-American architect and Pritzker laureate known whose modernist sensibility...

 
 
 
Pharma giants are betting billions on gene therapies that could fundamentally change how we treat diseases

PHARMA GIANTS ARE BETTING BILLIONS ON GENE THERAPIES THAT COULD FUNDAMENTALLY CHANGE HOW WE TREAT DISEASES

Pharma is getting serious about gene therapy, one-time treatments designed to modify genes to cure serious diseases. On Monday, Swiss...

 
 
 
Roche agrees to buy Philadelphia biotech Spark Therapeutics for $4.8 billion

ROCHE AGREES TO BUY PHILADELPHIA BIOTECH SPARK THERAPEUTICS FOR $4.8 BILLION

Spark Therapeutics Inc., founded by researchers from Children's Hospital of Philadelphia, has agreed to be sold to Switzerland-based...

Roche to buy Spark Therapeutics for $4.8 billion

ROCHE TO BUY SPARK THERAPEUTICS FOR $4.8 BILLION

Shares of Philadelphia-based Spark were up more than 120 percent in premarket trading on the Nasdaq following the news.

 
 
 
Pharma giant Roche just bought biotech firm Spark, the maker of an $850,000 eye drug

PHARMA GIANT ROCHE JUST BOUGHT BIOTECH FIRM SPARK, THE MAKER OF AN $850,000 EYE DRUG

Swiss pharmaceutical company Roche is set to purchase US gene therapy company Spark Therapeutics for approximately $4.8 billion. Spark...

Swiss drug giant Roche reportedly readies to buy the biotech behind the first FDA-approved gene therapy, which just became the priciest medicine in the US

SWISS DRUG GIANT ROCHE REPORTEDLY READIES TO BUY THE BIOTECH BEHIND THE FIRST FDA-APPROVED GENE THERAPY, WHICH JUST BECAME THE PRICIEST MEDICINE IN THE US

Swiss drugmaker Roche is nearing a deal to buy Philadelphia-based biotech company Spark Therapeutics , the Wall Street Journal reported...

 
 
 
Oscar De La Renta: Ready to Wear AW19

OSCAR DE LA RENTA: READY TO WEAR AW19

One thing is for sure - you can count on Oscar de la Renta to deliver what women want and perhaps what women didn't know they want!...

Modern Dolce Vita: Roch Barbot Fronts PT Pantaloni Torino Spring '19 Campaign

MODERN DOLCE VITA: ROCH BARBOT FRONTS PT PANTALONI TORINO SPRING '19 CAMPAIGN

Roch Barbot reunites with PT Pantaloni Torino for its spring-summer 2019 campaign. A couple's outing, PT also enlists model Lisa Fratani....